HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Donepezil improves learning and memory deficits in APP/PS1 mice by inhibition of microglial activation.

Abstract
Donepezil, a cholinesterase inhibitor, is a representative symptomatic therapy for Alzheimer's disease (AD). Recent studies have reported the anti-inflammatory effects of donepezil. However, limited studies that investigate its anti-inflammatory effect in AD have been reported. Considering the role of proinflammatory molecules and microglial activation in the pathogenesis of AD, the current study aimed to elucidate the effects of donepezil on microglial activation induced by amyloid deposition in transgenic mice. Our results showed that chronic treatment with donepezil significantly improved the cognitive function in the novel object recognition test and Morris water maze test in amyloid precursor protein (APP)/presenilin-1 (PS1) transgenic mice. We further demonstrated that these cognitive enhancements were related to the anti-inflammatory effect of donepezil. We found that donepezil could inhibit the expression of CD68, a specific marker of microglial activation, and reduce the release of proinflammatory cytokines including tumor necrosis factor-α and interleukin-1β. Immunohistochemistry and Congo red co-staining revealed that congophilic amyloid and activated microglia around plaques were also reduced by donepezil treatment. Enzyme-linked immunosorbent assay (ELISA) analysis showed that donepezil decreased insoluble Aβ40/Aβ42 and soluble Aβ40 levels. Moreover, donepezil reversed the impaired expression of insulin-degrading enzyme in the hippocampus of APP/PS1 mice. Our findings indicated that donepezil improves cognitive deficits in APP/PS1 mice by a mechanism that may be associated with its inhibition of microglial activation and release of proinflammatory cytokines.
AuthorsH B Guo, Y F Cheng, J G Wu, C M Wang, H T Wang, C Zhang, Z K Qiu, J P Xu
JournalNeuroscience (Neuroscience) Vol. 290 Pg. 530-42 (Apr 02 2015) ISSN: 1873-7544 [Electronic] United States
PMID25662507 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2015 IBRO. Published by Elsevier Ltd. All rights reserved.
Chemical References
  • APP protein, human
  • Amyloid beta-Peptides
  • Amyloid beta-Protein Precursor
  • Antigens, CD
  • Antigens, Differentiation, Myelomonocytic
  • CD68 protein, mouse
  • Cytokines
  • Indans
  • Nootropic Agents
  • PSEN1 protein, human
  • Peptide Fragments
  • Piperidines
  • Presenilin-1
  • amyloid beta-protein (1-40)
  • amyloid beta-protein (1-42)
  • Donepezil
Topics
  • Amyloid beta-Peptides (metabolism)
  • Amyloid beta-Protein Precursor (genetics, metabolism)
  • Animals
  • Antigens, CD (metabolism)
  • Antigens, Differentiation, Myelomonocytic (metabolism)
  • Brain (drug effects, physiopathology)
  • Cytokines (metabolism)
  • Donepezil
  • Indans (pharmacology)
  • Learning Disabilities (drug therapy, physiopathology)
  • Male
  • Maze Learning (drug effects, physiology)
  • Memory Disorders (drug therapy, physiopathology)
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Microglia (drug effects, physiology)
  • Neurites (drug effects, physiology)
  • Nootropic Agents (pharmacology)
  • Peptide Fragments (metabolism)
  • Piperidines (pharmacology)
  • Plaque, Amyloid (drug therapy, physiopathology)
  • Presenilin-1 (genetics, metabolism)
  • Random Allocation
  • Recognition, Psychology (drug effects, physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: